Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...

Fate Therapeutics, Inc. (NASDAQ:FATE) recently reported positive data from its phase 1 autoimmunity study using FT819 for the treatment of patients with moderate-to-severe Systemic Lupus ...

Fate Therapeutics (FATE) presented new clinical and translational data from the company’s FT819 Phase 1 Autoimmunity study for ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The ...

The change comes as the company reaffirms its commitment to developing new off-the-shelf cellular immunotherapies.

The company said the patient, an African American-Asian woman diagnosed with lupus nephritis, received fludarabine-free conditioning followed by a single dose of FT819. The woman achieved clinical ...

Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a T-cell product candidate for patients with systemic lupus ...

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate FT819.